Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898832 | 0.93 | LMNA (0.35) | LMNA | |
| SCHEMBL3855605 | 0.84 | — | — | |
| SCHEMBL3890572 | 0.83 | TSHR (0.39) | LMNA | |
| SCHEMBL21219903 | 0.83 | LMNA (0.35) | LMNA | |
| SCHEMBL2761263 | 0.83 | LMNA (0.46) | LMNA | |
| SCHEMBL28937911 | 0.83 | ACE2 (0.36) | LMNA | |
| SCHEMBL9366046 | 0.81 | LMNA (0.39) | LMNA | |
| SCHEMBL9739198 | 0.81 | ACE2 (0.44) | LMNA | |
| SCHEMBL27824731 | 0.81 | TSHR (0.48) | — | |
| SCHEMBL9414024 | 0.81 | TSHR (0.37) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | claimed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | claimed |
| US-9255059-B2 | Method for producing an alkyl 3-hydroxybutyrate | EASTMAN CHEMICAL COMPANY (US) | 2016-02-09 | — | — | US | claimed |
| US-9249378-B2 | Aqueous cleaning compositions having enhanced properties | EASTMAN CHEMICAL COMPANY (US) | 2016-02-02 | — | — | US | claimed |
| US-20150038734-A1 | METHOD FOR PRODUCING AN ALKYL 3-HYDROXYBUTYRATE | EASTMAN CHEMICAL COMPANY (US) | 2015-02-05 | — | — | US | claimed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | claimed |
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| CN-105755480-B | Efficient acidic cleaner | 江苏筑磊电子科技有限公司 | 2018-06-19 | — | — | CN | disclosed |
| US-9809521-B2 | Cannabidinoid derivatives | SUTTER WEST BAY HOSPITALS (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2016-12-29 | — | — | US | disclosed |
| US-9506017-B2 | Aqueous cleaning compositions including an alkyl 3-hydroxybutyrate | EASTMAN CHEMICAL COMPANY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9255241-B2 | Aqueous cleaning compositions including an alkyl 3-hydroxybutyrate | EASTMAN CHEMICAL COMPANY (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150038734-A1 | METHOD FOR PRODUCING AN ALKYL 3-HYDROXYBUTYRATE | EASTMAN CHEMICAL COMPANY (US) | 2015-02-05 | — | — | US | disclosed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | disclosed |
| US-20090149584-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-11 | — | — | US | disclosed |
| CN-101426843-A | Use of hexahydrophthalimide combinations as softener | BASF SE (DE) | 2009-05-06 | — | — | CN | disclosed |
| EP-2013278-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008006834-A2 | USE OF IMIDAZOLE COMPOUNDS AS PLASTICISERS | BASF SE (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007122204-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038734-A1 | METHOD FOR PRODUCING AN ALKYL 3-HYDROXYBUTYRATE | HSD17B10, ABAT, HSD17B12 | LMNA 3157/4885 |
| US-10202322-B2 | Resorcinol derivatives | CNR1, CNR2, RCOR1 | LMNA 3370/4885 |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | LMNA 2282/4885 |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | LMNA 2282/4885 |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | CNR1, CNR2, RCOR1 | LMNA 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.